Lumos Pharma Stock Forum

$Lumos Pharma (LUMO.US)$
Updated Phase 2 OraGrowtH Data Presented at ESPE 2024 Demonstrate Sustained Growth on Oral LUM-201 to 24 Months in PGHD and Correlation of Growth to LUM-201’s Unique Pulsatile Mechanism of Action
Lumos Pharma presented new analyses from Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials at ESPE 2024. The data showed sustained growth on LUM-201 in moderate Pediatric Growth Hormone Deficiency (PGHD) patients over 24 months. Results demonstrated significant increases ...

$Lumos Pharma (LUMO.US)$
Lumos Pharma | SC 13G: Statement of acquisition of beneficial ownership by individuals-Private Advisor Group, LLC(9.16%)

$Lumos Pharma (LUMO.US)$ Lumos Pharma Company and FDA Are Aligned on the Company's Final Phase 3 Trial Design >LUMO
Dow Jones· 3 mins ago

$Lumos Pharma (LUMO.US)$ Reuters· just
Lumos Pharma Enters Into Definitive Merger Agreement With Double Point Ventures to Go Private via a Tender Offer of $4.25 Cash per Share Plus Contingent Value Rights (CVR)

$Lumos Pharma (LUMO.US)$ 🤔

$Lumos Pharma (LUMO.US)$
Lumos Pharma Announces Abstract Accepted for Oral Presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society, APPES 2024
Lumos Pharma, Inc. (NASDAQ:LUMO) announced that an updated analysis of data from its Phase 2 OraGrowtH210 clinical trial has been accepted for presentation at the 13th Biennial Scientific Meeting of the Asia Pacific Pediatric Endocrine Society (APPES 2024). The event will take place from October 2-5, 2024, i...

$Lumos Pharma (LUMO.US)$
I'm holding a little. hope gradually 🛫✌️

$Lumos Pharma (LUMO.US)$
Lumos Pharma Announces New Analyses of Phase 2 OraGrowtH212 Trial Presented at ENDO 2024
Lumos Pharma presented new analyses of its Phase 2 OraGrowtH212 trial at the ENDO 2024 meeting. The data reveals that oral LUM-201 significantly increased growth hormone (GH) secretion in children with moderate Pediatric Growth Hormone Deficiency (PGHD) over six months. The treatment restored GH levels to near-normal compared to healthy children, with lower GH exposure than tradit...

$Lumos Pharma (LUMO.US)$ Reuters· just
Lumos Pharma Inc: Outcome From End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial